The results showed that Cy5-Ark2 could colocalize with trastuzumab in HER2-positive SK-BR-3 and MCF7-HER2 tumor tissues, while no obvious staining signals were detected in HER2-negative MCF7 tumor tissues (Additional file 1: Figure S7). Here, AURKB is linked to neoplasm.